Fundamental Analysis of GLYCOMIMETICS INC(NASDAQ:GLYC) stock

Fundamental Rating

GLYC gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. The financial health of GLYC is average, but there are quite some concerns on its profitability. GLYC does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

GLYC had negative earnings in the past year.

GLYC had a negative operating cash flow in the past year.

GLYC had negative earnings in each of the past 5 years.

GLYC had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

GLYC's Return On Assets of -81.42% is on the low side compared to the rest of the industry. GLYC is outperformed by 71.48% of its industry peers.

GLYC's Return On Equity of -96.05% is in line compared to the rest of the industry. GLYC outperforms 46.88% of its industry peers.

		Industry Rank	Sector Rank
ROA	-81.42%
ROE	-96.05%
ROIC	N/A

ROA(3y)-79.61%

ROA(5y)-61.8%

ROE(3y)-94.21%

ROE(5y)-71.99%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

GLYC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

GLYC does not have a ROIC to compare to the WACC, probably because it is not profitable.

GLYC has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, GLYC has more shares outstanding

There is no outstanding debt for GLYC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

GLYC has an Altman-Z score of -14.13. This is a bad value and indicates that GLYC is not financially healthy and even has some risk of bankruptcy.

GLYC has a worse Altman-Z score (-14.13) than 81.11% of its industry peers.

GLYC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-14.13

ROIC/WACCN/A

WACC10.41%

2.3 Liquidity

A Current Ratio of 6.41 indicates that GLYC has no problem at all paying its short term obligations.

GLYC has a better Current ratio (6.41) than 65.78% of its industry peers.

GLYC has a Quick Ratio of 6.41. This indicates that GLYC is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of GLYC (6.41) is better than 65.95% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	6.41
Quick Ratio	6.41

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 6.15% over the past year.

GLYC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -87.50%.

Measured over the past years, GLYC shows a very negative growth in Revenue. The Revenue has been decreasing by -90.05% on average per year.

EPS 1Y (TTM)6.15%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-23.08%

Revenue 1Y (TTM)-87.5%

Revenue growth 3Y-90.05%

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GLYC will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.89% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-6.84%

EPS Next 2Y11.13%

EPS Next 3Y3.33%

EPS Next 5Y11.89%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

GLYC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year GLYC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y11.13%

EPS Next 3Y3.33%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for GLYC!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GLYCOMIMETICS INC

NASDAQ:GLYC (11/21/2024, 8:00:01 PM)

After market: 0.3267 +0.01 (+2.09%)

0.32

-0.01 (-3.03%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap20.63M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-81.42%
ROE	-96.05%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	6.41
Quick Ratio	6.41
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)6.15%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y-6.84%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-87.5%

Revenue growth 3Y-90.05%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

GLYCOMIMETICS INC (GLYC)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens